Critical care (Houten, Netherlands)最新文献_第2页

Comparison of 6-month outcomes of sepsis versus non-sepsis critically ill patients receiving mechanical ventilation. 脓毒症与非脓毒症危重症患者接受机械通气6个月预后的比较

Critical care (Houten, Netherlands) Pub Date : 2022-06-13 DOI: 10.1186/s13054-022-04041-w

Carol L Hodgson, Alisa M Higgins, Michael Bailey, Jonathon Barrett, Rinaldo Bellomo, D James Cooper, Belinda J Gabbe, Theodore Iwashyna, Natalie Linke, Paul S Myles, Michelle Paton, Steve Philpot, Mark Shulman, Meredith Young, Ary Serpa Neto

{"title":"Comparison of 6-month outcomes of sepsis versus non-sepsis critically ill patients receiving mechanical ventilation.","authors":"Carol L Hodgson, Alisa M Higgins, Michael Bailey, Jonathon Barrett, Rinaldo Bellomo, D James Cooper, Belinda J Gabbe, Theodore Iwashyna, Natalie Linke, Paul S Myles, Michelle Paton, Steve Philpot, Mark Shulman, Meredith Young, Ary Serpa Neto","doi":"10.1186/s13054-022-04041-w","DOIUrl":"10.1186/s13054-022-04041-w","url":null,"abstract":"Background: Data on long-term outcomes after sepsis-associated critical illness have mostly come from small cohort studies, with no information about the incidence of new disability. We investigated whether sepsis-associated critical illness was independently associated with new disability at 6 months after ICU admission compared with other types of critical illness.Methods: We conducted a secondary analysis of a multicenter, prospective cohort study in six metropolitan intensive care units in Australia. Adult patients were eligible if they had been admitted to the ICU and received more than 24 h of mechanical ventilation. There was no intervention.Results: The primary outcome was new disability measured with the WHO Disability Assessment Schedule 2.0 (WHODAS) 12 level score compared between baseline and 6 months. Between enrollment and follow-up at 6 months, 222/888 (25%) patients died, 100 (35.5%) with sepsis and 122 (20.1%) without sepsis (P < 0.001). Among survivors, there was no difference for the incidence of new disability at 6 months with or without sepsis, 42/106 (39.6%) and 106/300 (35.3%) (RD, 0.00 (- 10.29 to 10.40), P = 0.995), respectively. In addition, there was no difference in the severity of disability, health-related quality of life, anxiety and depression, post-traumatic stress, return to work, financial distress or cognitive function.Conclusions: Compared to mechanically ventilated patients of similar acuity and length of stay without sepsis, patients with sepsis admitted to ICU have an increased risk of death, but survivors have a similar risk of new disability at 6 months. Trial registration NCT03226912, registered July 24, 2017.","PeriodicalId":92888,"journal":{"name":"Critical care (Houten, Netherlands)","volume":" ","pages":"174"},"PeriodicalIF":0.0,"publicationDate":"2022-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43993140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early versus delayed enteral nutrition in mechanically ventilated patients with circulatory shock: a nested cohort analysis of an international multicenter, pragmatic clinical trial 机械通气伴循环休克患者早期与延迟肠内营养:一项国际多中心实用临床试验的嵌套队列分析

Critical care (Houten, Netherlands) Pub Date : 2022-06-09 DOI: 10.1186/s13054-022-04047-4

L. Ortiz-Reyes, J. Patel, Xuran Jiang, Angel O Coz Yataco, A. Day, F. Shah, J. Zelten, M. Tamae-Kakazu, T. Rice, D. Heyland

引用次数: 14

Reply to: “Hyperoxemia in postsurgical sepsis/septic shock patients is associated with reduced mortality” 回复:“术后败血症/感染性休克患者的高氧血症与死亡率降低相关”

Critical care (Houten, Netherlands) Pub Date : 2022-06-09 DOI: 10.1186/s13054-022-03989-z

A. Franciosi, C. McCarthy, R. Macredmond

引用次数: 0

Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein. 重组ACE2蛋白对严重急性呼吸系统综合征冠状病毒2型刺突RBD蛋白诱导的急性肺损伤的保护作用

Critical care (Houten, Netherlands) Pub Date : 2022-06-09 DOI: 10.1186/s13054-022-04034-9

Lingbing Zhang, Yandan Zhang, Xia Qin, Xuejun Jiang, Jun Zhang, Lejiao Mao, Ziqi Jiang, Yu Jiang, Gang Liu, Jingfu Qiu, Chengzhi Chen, Feng Qiu, Zhen Zou

{"title":"Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein.","authors":"Lingbing Zhang, Yandan Zhang, Xia Qin, Xuejun Jiang, Jun Zhang, Lejiao Mao, Ziqi Jiang, Yu Jiang, Gang Liu, Jingfu Qiu, Chengzhi Chen, Feng Qiu, Zhen Zou","doi":"10.1186/s13054-022-04034-9","DOIUrl":"10.1186/s13054-022-04034-9","url":null,"abstract":"Background: SARS-CoV-2 infection leads to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Both clinical data and animal experiments suggest that the renin-angiotensin system (RAS) is involved in the pathogenesis of SARS-CoV-2-induced ALI. Angiotensin-converting enzyme 2 (ACE2) is the functional receptor for SARS-CoV-2 and a crucial negative regulator of RAS. Recombinant ACE2 protein (rACE2) has been demonstrated to play protective role against SARS-CoV and avian influenza-induced ALI, and more relevant, rACE2 inhibits SARS-CoV-2 proliferation in vitro. However, whether rACE2 protects against SARS-CoV-2-induced ALI in animal models and the underlying mechanisms have yet to be elucidated.Methods and results: Here, we demonstrated that the SARS-CoV-2 spike receptor-binding domain (RBD) protein aggravated lipopolysaccharide (LPS)-induced ALI in mice. SARS-CoV-2 spike RBD protein directly binds and downregulated ACE2, leading to an elevation in angiotensin (Ang) II. AngII further increased the NOX1/2 through AT1R, subsequently causing oxidative stress and uncontrolled inflammation and eventually resulting in ALI/ARDS. Importantly, rACE2 remarkably reversed SARS-CoV-2 spike RBD protein-induced ALI by directly binding SARS-CoV-2 spike RBD protein, cleaving AngI or cleaving AngII.Conclusion: This study is the first to prove that rACE2 plays a protective role against SARS-CoV-2 spike RBD protein-aggravated LPS-induced ALI in an animal model and illustrate the mechanism by which the ACE2-AngII-AT1R-NOX1/2 axis might contribute to SARS-CoV-2-induced ALI.","PeriodicalId":92888,"journal":{"name":"Critical care (Houten, Netherlands)","volume":" ","pages":"171"},"PeriodicalIF":0.0,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47924820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pentraxin-3 as a predictive marker of mortality in sepsis: an updated systematic review and meta-analysis Pentraxin-3作为败血症死亡率的预测标志物：一项最新的系统综述和荟萃分析

Critical care (Houten, Netherlands) Pub Date : 2022-06-08 DOI: 10.1186/s13054-022-04032-x

Guobin Wang, Chunyan Jiang, Junjun Fang, Zhitao Li, H. Cai

引用次数: 4

Lack of SARS-CoV-2-specific cellular response in critically ill COVID-19 patients despite apparent effective vaccination 尽管疫苗接种明显有效，但COVID-19危重患者缺乏sars - cov -2特异性细胞反应

Critical care (Houten, Netherlands) Pub Date : 2022-06-08 DOI: 10.1186/s13054-022-04038-5

F. Bidar, G. Monneret, F. Berthier, A. Lukaszewicz, F. Venet

引用次数: 3

Resilience is a dirty word: misunderstood, and how we can truly build it. 韧性是一个肮脏的词：被误解了，以及我们如何才能真正建立它

Critical care (Houten, Netherlands) Pub Date : 2022-06-08 DOI: 10.1186/s13054-022-04040-x

Mark Z Y Tan

引用次数: 0

Early intubation and patient-centered outcomes in septic shock: a secondary analysis of a prospective multicenter study 脓毒性休克的早期插管和以患者为中心的结局:一项前瞻性多中心研究的二次分析

Critical care (Houten, Netherlands) Pub Date : 2022-06-07 DOI: 10.1186/s13054-022-04029-6

R. Mellado-Artigas, C. Ferrando, F. Martino, A. Delbove, B. Ferreyro, C. Darreau, S. Jacquier, L. Brochard, N. Lerolle

引用次数: 4

Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial. 基线血浆IL-18可预测ARDS患者的辛伐他汀治疗反应：HARP-2随机临床试验的二次分析

Critical care (Houten, Netherlands) Pub Date : 2022-06-07 DOI: 10.1186/s13054-022-04025-w

Andrew James Boyle, Peter Ferris, Ian Bradbury, John Conlon, Manu Shankar-Hari, Angela J Rogers, Cecilia M O'Kane, Daniel F McAuley

{"title":"Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial.","authors":"Andrew James Boyle, Peter Ferris, Ian Bradbury, John Conlon, Manu Shankar-Hari, Angela J Rogers, Cecilia M O'Kane, Daniel F McAuley","doi":"10.1186/s13054-022-04025-w","DOIUrl":"10.1186/s13054-022-04025-w","url":null,"abstract":"Background: Interleukin (IL)-18 is a marker of inflammasome activation, and high baseline plasma IL-18 is associated with increased mortality in patients with sepsis-induced ARDS. The aim of this analysis was to determine if simvastatin was associated with benefit in patients with ARDS and high plasma IL-18.Methods: In this secondary analysis of the HARP-2 study, we compared 28-day mortality and response to simvastatin according to baseline plasma IL-18 using cox proportional hazards analysis. Separately, monocyte-derived macrophages from healthy volunteers were pre-incubated with simvastatin or rosuvastatin before stimulation with ATP and LPS, and the effect on secreted IL-18 and IL-1β compared.Results: 511 patients from HARP-2 had available data. High baseline plasma IL-18 (≥ 800 pg/ml) was associated with increased 28-day mortality (high IL-18 30.6% vs. low IL-18 17.5%; HR 1.89 [95% CI 1.30-2.73]; p = 0.001). Allocation to simvastatin in patients with high baseline plasma IL-18 was associated with a lower probability of 28-day mortality compared with placebo (24.0% vs 36.8%; p = 0.01). Finally, simvastatin, but not rosuvastatin, reduced stimulated macrophage secretion of IL-18 and IL-1β.Conclusion: In patients with high baseline plasma IL-18, simvastatin is associated with a higher probability of survival, and this effect may be due to reduced inflammasome activation. These data suggest that baseline plasma IL-18 may allow a personalised treatment approach by identifying patients with ARDS who could benefit from simvastatin therapy.","PeriodicalId":92888,"journal":{"name":"Critical care (Houten, Netherlands)","volume":" ","pages":"164"},"PeriodicalIF":0.0,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49328790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An interventional quasi-experimental study to evaluate the impact of a rapid screening strategy in improving control of nosocomial extended-spectrum beta-lactamase-producing Enterobacterales and carbapenemase-producing organisms in critically ill patients 一项介入性准实验研究，评估快速筛查策略对改善危重患者院内广谱产β -内酰胺酶肠杆菌和产碳青霉烯酶微生物控制的影响

Critical care (Houten, Netherlands) Pub Date : 2022-06-07 DOI: 10.1186/s13054-022-04027-8

R. Martischang, P. François, A. Cherkaoui, G. Renzi, C. Fankhauser, J. Schrenzel, J. Pugin, S. Harbarth

引用次数: 0